Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at…
DEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for…